JP2017523796A5 - - Google Patents

Download PDF

Info

Publication number
JP2017523796A5
JP2017523796A5 JP2017506955A JP2017506955A JP2017523796A5 JP 2017523796 A5 JP2017523796 A5 JP 2017523796A5 JP 2017506955 A JP2017506955 A JP 2017506955A JP 2017506955 A JP2017506955 A JP 2017506955A JP 2017523796 A5 JP2017523796 A5 JP 2017523796A5
Authority
JP
Japan
Prior art keywords
seq
following sequence
encephalitis virus
structural protein
equine encephalitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017506955A
Other languages
English (en)
Japanese (ja)
Other versions
JP6824154B2 (ja
JP2017523796A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2015/003997 external-priority patent/WO2016021209A1/en
Publication of JP2017523796A publication Critical patent/JP2017523796A/ja
Publication of JP2017523796A5 publication Critical patent/JP2017523796A5/ja
Application granted granted Critical
Publication of JP6824154B2 publication Critical patent/JP6824154B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017506955A 2014-08-08 2015-08-07 修飾エンベロープタンパク質ｅ３を含むウイルス様粒子 Active JP6824154B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201462035037P 2014-08-08 2014-08-08
US62/035,037 2014-08-08
US201462079128P 2014-11-13 2014-11-13
US62/079,128 2014-11-13
US201562101514P 2015-01-09 2015-01-09
US62/101,514 2015-01-09
US201562120569P 2015-02-25 2015-02-25
US62/120,569 2015-02-25
US201562198949P 2015-07-30 2015-07-30
US62/198,949 2015-07-30
PCT/JP2015/003997 WO2016021209A1 (en) 2014-08-08 2015-08-07 Virus like particle comprising modified envelope protein e3

Publications (3)

Publication Number Publication Date
JP2017523796A JP2017523796A (ja) 2017-08-24
JP2017523796A5 true JP2017523796A5 (enExample) 2018-09-06
JP6824154B2 JP6824154B2 (ja) 2021-02-03

Family

ID=55263499

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017506955A Active JP6824154B2 (ja) 2014-08-08 2015-08-07 修飾エンベロープタンパク質ｅ３を含むウイルス様粒子

Country Status (6)

Country Link
US (1) US9969986B2 (enExample)
EP (1) EP3177720B1 (enExample)
JP (1) JP6824154B2 (enExample)
CN (1) CN106795513B (enExample)
TW (1) TWI720946B (enExample)
WO (1) WO2016021209A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013221187B9 (en) 2012-02-16 2018-01-04 Vlp Therapeutics, Inc. Virus like particle composition
EP3004348B1 (en) 2013-06-03 2023-03-08 VLP Therapeutics, Inc. Malaria vaccine
TWI676636B (zh) 2013-07-12 2019-11-11 Ｖｌｐ醫療股份有限公司 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子
CN105792842B (zh) 2013-10-11 2020-06-02 美利坚合众国, 由健康及人类服务部部长代表 埃巴病毒疫苗
CN106795513B (zh) 2014-08-08 2021-06-11 Vlp治疗公司 包含修饰的包膜蛋白e3的病毒样颗粒
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
CA2960102C (en) 2014-09-11 2023-10-24 Vlp Therapeutics, Llc Flavivirus virus like particle
AU2015373928B2 (en) 2014-12-31 2019-10-17 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Novel multivalent nanoparticle-based vaccines
US10166281B2 (en) 2015-09-04 2019-01-01 Vlp Therapeutics, Llc Method and composition for modulating immune response
WO2017150683A1 (en) * 2016-03-04 2017-09-08 Vlp Therapeutics, Llc Zika virus virus like particle
WO2017221076A1 (en) * 2016-06-24 2017-12-28 Institut Pasteur Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases
JP7183149B2 (ja) 2016-09-02 2022-12-05 ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンテッド・バイ・ザ・セクレタリー・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシーズ 安定化されたグループ２インフルエンザヘマグルチニンステム領域三量体およびその使用
US11129886B2 (en) 2017-03-28 2021-09-28 Children's Hospital Medical Center VLP-based bivalent Ebola vaccines and methods of making and using same
CN118909082A (zh) * 2017-03-28 2024-11-08 俄亥俄州创新基金会 一种分离的肽
WO2019124441A1 (en) * 2017-12-20 2019-06-27 Vlp Therapeutics, Llc Alphavirus replicon particle
CN112203681B (zh) * 2018-02-07 2024-05-24 免疫基因有限公司 疫苗组合物及其用途
WO2019156223A1 (ja) * 2018-02-09 2019-08-15 国立大学法人大阪大学 チクングニアウイルスに対する抗体またはその抗原結合断片、およびその用途
FR3078536A1 (fr) * 2018-03-05 2019-09-06 Peptinov Sas Composition vaccinale anti-pd-1
FR3078535B1 (fr) * 2018-03-05 2024-02-09 Peptinov Sas Composition vaccinale anti-pd-l1
CN109536464B (zh) * 2018-12-10 2022-06-10 中国科学院武汉病毒研究所 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用
EP4135847A4 (en) 2020-04-17 2024-05-15 VLP Therapeutics, Inc. Coronavirus vaccine
CA3174651A1 (en) 2020-04-30 2021-11-04 Vlp Therapeutics, Inc. Cytokine immunotherapy
WO2022225057A1 (en) * 2021-04-23 2022-10-27 Vlp Therapeutics, Inc. Galectin-targeting immunotherapy
CN115466330B (zh) * 2021-06-10 2023-10-20 清华大学 一种基于病毒样颗粒呈递冠状病毒受体结合区的冠状病毒亚单位疫苗
WO2023009505A1 (en) * 2021-07-26 2023-02-02 Beam Therapeutics Inc. Pseudotyped recombinant lyssaviruses for gene therapy
EP4511479A1 (en) * 2022-04-18 2025-02-26 Cyn-K Bio, Inc. Treatment of inflammatory conditions
CN116042657A (zh) * 2023-01-16 2023-05-02 上海复诺健生物科技有限公司 自复制信使核糖核酸疫苗
WO2025084276A1 (ja) * 2023-10-16 2025-04-24 Ｃｙｎ－Ｋバイオ株式会社 肥満の処置

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8923123D0 (en) 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
EP0614465B1 (en) 1991-11-16 1999-03-17 SMITHKLINE BEECHAM BIOLOGICALS s.a. HYBRID PROTEIN BETWEEN CS FROM PLASMODIUM AND HBsAG
US5580773A (en) 1992-06-17 1996-12-03 Korea Green Cross Corporation Chimeric immunogenic gag-V3 virus-like particles of the human immunodeficiency virus (HIV)
CA2143491C (en) 1994-03-01 2011-02-22 Yasumasa Ishida A novel peptide related to human programmed cell death and dna encoding it
JPH11513249A (ja) 1995-09-27 1999-11-16 メディカル・リサーチ・カウンシル プロテアーゼにより開裂可能なタンパク質を組込んだ組換えウイルス
CA2320958A1 (en) 1998-02-11 1999-08-19 Maxygen, Inc. Antigen library immunization
WO2001014557A1 (en) 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
EP1390398A2 (en) 2001-05-30 2004-02-25 Transgene S.A. Adenovirus protein ix, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization
EP2206517B1 (en) 2002-07-03 2023-08-02 Ono Pharmaceutical Co., Ltd. Immunopotentiating compositions comprising anti-PD-L1 antibodies
EP1583500A4 (en) 2002-11-13 2008-02-13 Us Navy METHOD AND COMPOSITIONS FOR INDUCTION OF IMMUNE REACTIONS AND PROTECTION IMMUNITY BY PRIMING WITH ALPHAVIRUS REPLICONIC VACCINES
US7790181B2 (en) * 2003-05-29 2010-09-07 The United States Of America As Represented By The Secretary Of The Army Live attenuated viral vaccines for Eastern Equine Encephalitis virus
CN101151272A (zh) 2003-12-01 2008-03-26 陶氏环球技术公司 在假单胞菌中生产重组二十面体病毒样颗粒
ES2371175T3 (es) 2004-10-14 2011-12-28 Crucell Holland B.V. Vacunas de sensibilización/refuerzo de malaria.
US20090298955A1 (en) 2005-02-16 2009-12-03 Konica Minolta Holdings, Inc. Altered virus capsid protein and use thereof
CN104436190A (zh) 2005-06-08 2015-03-25 达纳-法伯癌症研究院公司 通过抑制程序性细胞死亡1(pd-1)途经治疗持续性感染和癌症的方法及组合物
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
CU23586A1 (es) 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
WO2007100098A1 (ja) 2006-03-03 2007-09-07 Kyoto University 細胞表面機能分子の細胞外領域多量体
AU2007291936B2 (en) 2006-08-30 2012-09-27 Artes Biotechnology Gmbh Recombinant proteins and virus like particles comprising L and S polypeptides of avian hepadnaviridae and methods, nucleic acid constructs, vectors and host cells for producing same
AU2008338803B2 (en) 2007-11-26 2015-02-05 Glaxosmithkline Biologicals S.A. Methods of generating alphavirus particles
CN107574156A (zh) * 2008-11-26 2018-01-12 美国国有健康与人类服务部 类病毒组合物颗粒及其使用方法
WO2010077717A1 (en) * 2008-12-09 2010-07-08 Novavax, Inc. Modified rsv f proteins and methods of their use
US20120219579A1 (en) 2009-09-18 2012-08-30 Fraunhofer Usa Inc. Virus like particles comprising target proteins fused to plant viral coat proteins
WO2012006180A1 (en) 2010-06-29 2012-01-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv immunogens
WO2012023995A1 (en) 2010-08-18 2012-02-23 Takayuki Shiratsuchi Modification of recombinant adenovirus capsid protein with immunogenic plasmodium circumsporozoite protein epitopes
US9487563B2 (en) 2011-01-31 2016-11-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Virus-like particles and methods of use
US9402916B2 (en) 2011-03-17 2016-08-02 The University Of Birmingham Re-directed immunotherapy
WO2012172574A1 (en) 2011-06-17 2012-12-20 Bharat Biotech International Limited Vaccine composition comprising an inactivated chikungunya virus strain
CN102321639B (zh) 2011-09-08 2013-06-26 中国疾病预防控制中心病毒病预防控制所 基孔肯雅病毒病毒样颗粒的制备方法和应用
US20150265694A1 (en) 2011-10-25 2015-09-24 Florida Gulf Coast University Board Of Trustees Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypes
AU2013221187B9 (en) 2012-02-16 2018-01-04 Vlp Therapeutics, Inc. Virus like particle composition
EP2834265A4 (en) 2012-04-02 2015-10-14 Univ North Carolina METHOD AND COMPOSITIONS FOR DENGUE VIRUS EPITOPES
SI2850431T1 (en) 2012-05-16 2018-08-31 Immune Design Corp. Vaccines for hsv-2
EP3004348B1 (en) 2013-06-03 2023-03-08 VLP Therapeutics, Inc. Malaria vaccine
TWI676636B (zh) 2013-07-12 2019-11-11 Ｖｌｐ醫療股份有限公司 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子
US10060924B2 (en) 2014-03-18 2018-08-28 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Distinguishing flavivirus infection using a recombinant mutant envelope protein
CN106795513B (zh) 2014-08-08 2021-06-11 Vlp治疗公司 包含修饰的包膜蛋白e3的病毒样颗粒
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
US9363353B1 (en) 2014-12-04 2016-06-07 Hon Man Ashley Chik Mobile phone docks with multiple circulating phone connectors
AU2015373928B2 (en) 2014-12-31 2019-10-17 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Novel multivalent nanoparticle-based vaccines
US20180339038A1 (en) 2015-06-12 2018-11-29 Mie University Human parainfluenza virus type 2 vector and vaccine
US10799575B2 (en) 2015-06-25 2020-10-13 Technovax, Inc. Flavivirus and alphavirus virus-like particles (VLPS)
MY187459A (en) 2015-07-16 2021-09-23 Bharat Biotech Int Ltd Vaccine compositions
EP4218805A1 (en) 2015-07-21 2023-08-02 ModernaTX, Inc. Infectious disease vaccines
CN106085974B (zh) 2016-06-07 2019-08-09 博奥生物集团有限公司 一种寨卡病毒假病毒颗粒及其制备方法

Similar Documents

Publication Publication Date Title
JP2017523796A5 (enExample)
SG11202003746UA (en) Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
JP2019194236A5 (enExample)
JP2017048194A5 (enExample)
JP2018024670A5 (enExample)
SG11202003700TA (en) Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
JP2017514877A5 (enExample)
EA201790630A1 (ru) Способы получения рибозидов
LT3577124T (lt) Nukleotido hemisulfato druska, skirta hepatito c virusui gydyti
MX2022006652A (es) Proteinas de capside modificadas para un suministro mejorado de vectores de parvovirus.
JP2016525888A5 (enExample)
JP2019524645A5 (enExample)
JP2016153424A5 (enExample)
JP2017008120A5 (enExample)
JP2017532302A5 (enExample)
EA201890527A1 (ru) Терапевтические вакцины против hpv18
LT3512863T (lt) 2'-pakeistieji-n6-pakeistieji purino nukleotidai, skirti gydymui rnr virusu
JP2014028813A5 (enExample)
EP3148566C0 (en) LONG SYNTHETIC PEPTIDES (SLP) FOR THERAPEUTIC VACCINATION PURPOSES AGAINST HEPATITIS B VIRUS INFECTION
WO2015052543A3 (en) Malaria vaccination
JP2017501211A5 (enExample)
JP2018116258A5 (enExample)
JP2018030858A5 (enExample)
JP2017227899A5 (enExample)
SI3400225T1 (sl) Pentanojske kisline substituirane s pirolo-(2-3,b)pirimidin-piridini za zdravljenje okužb z virusom gripe